Huseyin Naci

Huseyin Naci publication distribution in Economics and Finance in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Economics and Finance in 2026. The highlighted bar marks where Huseyin Naci sits on this spectrum.

Huseyin Naci D-index placement in Economics and Finance in 2026

The chart shows the D-index (discipline H-index) distribution of Economics and Finance scientists ranked by Research.com in 2026. The highlighted bar marks where Huseyin Naci sits on this spectrum.

Best Publications

• Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13

  Courtney Davis;Huseyin Naci;Evrim Gurpinar;Elita Poplavska

  668
  Citations

• From "retailers" to health care providers: Transforming the role of community pharmacists in chronic disease management.

  Elias Mossialos;Emilie Courtin;Huseyin Naci;Shalom Benrimoj

  539
  Citations

• Distribution of road traffic deaths by road user group: a global comparison

  H. Naci;Dan Chisholm;Timothy D. Baker

  436
  Citations

• Economic burden of multiple sclerosis: a systematic review of the literature.

  Huseyin Naci;Rachael Fleurence;Julie Birt;Amy Duhig

  265
  Citations

• Comparative benefits of statins in the primary and secondary prevention of major coronary events and all-cause mortality: a network meta-analysis of placebo-controlled and active-comparator trials

  Huseyin Naci;Jasper J Brugts;Rachael Fleurence;Bernice Tsoi

  261
  Citations

• Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis.

  Huseyin Naci;Huseyin Naci;Courtney Davis;Jelena Savović;Jelena Savović;Julian P T Higgins;Julian P T Higgins;Julian P T Higgins

  253
  Citations

• Characteristics of Preapproval and Postapproval Studies for Drugs Granted Accelerated Approval by the US Food and Drug Administration.

  Huseyin Naci;Katelyn R. Smalley;Aaron S. Kesselheim

  191
  Citations

• Cost effectiveness of strategies to combat road traffic injuries in sub-Saharan Africa and South East Asia: mathematical modelling study

  Daniel Chisholm;Huseyin Naci;Adnan Ali Hyder;Nhan T. Tran

  106
  Citations

• How good is "evidence" from clinical studies of drug effects and why might such evidence fail in the prediction of the clinical utility of drugs?

  Huseyin Naci;John P.A. Ioannidis

  92
  Citations

• Improving clinical trials for cardiovascular diseases: a position paper from the Cardiovascular Round Table of the European Society of Cardiology.

  Neville Jackson;Dan Atar;Maria Borentain;Guenter Breithardt

  91
  Citations

• Cost Implications of Using Different ECG Criteria for Screening Young Athletes in the United Kingdom.

  Harshil Dhutia;Aneil Malhotra;Vincent Gabus;Ahmed Merghani

  86
  Citations

• The Critical Role Of Observational Evidence In Comparative Effectiveness Research

  Rachael L. Fleurence;Huseyin Naci;Jeroen P. Jansen

  85
  Citations

• Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States

  Maximilian Salcher-Konrad;Huseyin Naci;Courtney Davis

  79
  Citations

• Generating comparative evidence on new drugs and devices after approval

  Andrea Cipriani;Andrea Cipriani;John P A Ioannidis;Peter M Rothwell;Paul Glasziou

  78
  Citations

• Decision Making Under Uncertainty: Comparing Regulatory and Health Technology Assessment Reviews of Medicines in the United States and Europe.

  Rick A Vreman;Huseyin Naci;Huseyin Naci;Wim G Goettsch;Aukje K Mantel-Teeuwisse

  75
  Citations

• Applying Multiple Criteria Decision Analysis to Comparative Benefit-Risk Assessment: Choosing among Statins in Primary Prevention.

  Tommi Tervonen;Huseyin Naci;Gert van Valkenhoef;Anthony E. Ades

  67
  Citations

• The impact of increasing neurological disability of multiple sclerosis on health utilities: a systematic review of the literature.

  Huseyin Naci;Rachael Fleurence;Julie Birt;Amy Duhig

  66
  Citations

• Evidence of comparative efficacy should have a formal role in European drug approvals

  Corinna Sorenson;Huseyin Naci;Jonathan Cylus;Elias Mossialos

  63
  Citations

• Generating comparative evidence on new drugs and devices before approval

  Huseyin Naci;Maximilian Salcher-Konrad;Aaron Kesselheim;Beate Wieseler

  58
  Citations

• Timing and Characteristics of Cumulative Evidence Available on Novel Therapeutic Agents Receiving Food and Drug Administration Accelerated Approval.

  Huseyin Naci;Olivier J. Wouters;Radhika Gupta;John P.A. Ioannidis

  42
  Citations